Leadership Transition at Adagio Medical
Adagio Medical Holdings, Inc. (NASDAQ: ADGM), a reputable innovator in catheter ablation technologies for treating cardiac arrhythmias, has made a significant leadership change recently. The departure of founder Olav Bergheim from the position of Chief Executive Officer and Chairperson of the Board marks a new chapter for the organization. In a strategic move, Todd Usen has been appointed as the new Chief Executive Officer and Director, taking the reins from Bergheim, effective December 13, 2024. Alongside Usen’s appointment, Orly Mishan will take charge as the Chairperson of the Board of Directors.
Celebrating Olav Bergheim's Contributions
During his tenure, Olav Bergheim was pivotal in establishing a solid foundation for Adagio Medical. His leadership brought remarkable clinical advancements and operational gains, ultimately leading the company to its current NASDAQ listing. "We appreciate Olav's unwavering dedication and valuable contributions to Adagio throughout the years," said Orly Mishan, expressing gratitude for Bergheim's impactful legacy. As he transitions out, Bergheim will assume an advisory role, guiding Usen through this critical period until December 2025.
Welcoming Todd Usen
Todd Usen, known for his extensive experience in the medical device sector, is well-prepared to lead Adagio into its next phase. His previous role as President & CEO of Minerva Surgical showcased his capability to steer organizations toward significant growth and operational restructuring. Furthermore, his leadership at Activ Surgical demonstrates his ability to obtain FDA and CE clearances along with securing substantial financial investments exceeding $92 million. Usen's past experience includes successful leadership roles at Olympus Corporation, Smith and Nephew, and Boston Scientific Corporation.
Usen's Vision for Adagio Medical
Expressing his excitement about joining Adagio, Usen stated, "I’m thrilled to join Adagio at this important junction in the Company’s history, supporting our initial commercial endeavors in Europe and the enrollment for the FULCRUM-VT trial in the United States." He believes that the evidence supporting Adagio's Ultra-Low Temperature Cryoablation technology will pave the way for the VT Cryoablation System with vCLAS™ catheter to become the industry standard for treating ventricular tachycardia.
About Adagio Medical Holdings, Inc.
Adagio Medical Holdings, Inc. (NASDAQ: ADGM) is dedicated to developing groundbreaking cryoablation technologies aimed at treating various cardiac arrhythmias. Located in Laguna Hills, California, the company focuses on creating seamless and effective treatment options for conditions such as paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
Exploring the FULCRUM-VT Study
The FULCRUM-VT trial, officially known as the Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia, is a crucial multi-center study aimed at enrolling 206 patients suffering from structural heart disease, both ischemic and non-ischemic. This pivotal study will assist in obtaining FDA premarket approval for Adagio’s VT Cryoablation System with vCLAS™ cryoablation catheter, an innovative solution for treating drug-refractory ventricular tachycardia.
Frequently Asked Questions
Who is the new CEO of Adagio Medical?
Todd Usen has been appointed as the new Chief Executive Officer of Adagio Medical.
What role did Olav Bergheim serve before his departure?
Olav Bergheim served as the Chief Executive Officer and Chairperson of the Board before his departure.
What is the focus of Adagio Medical Holdings, Inc.?
Adagio Medical specializes in developing innovative cryoablation technologies for treating cardiac arrhythmias.
What is the FULCRUM-VT trial?
The FULCRUM-VT trial is a prospective study aimed at assessing the effectiveness of Adagio's cryoablation technology for ventricular tachycardia.
How long will Olav Bergheim remain with Adagio Medical?
Olav Bergheim will serve as an advisor and assist Todd Usen with the transition until December 2025.
